

Hans-joachim, Schmoll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1775339/publications.pdf>

Version: 2024-02-01

169
papers

12,239
citations

38742

50
h-index

25787

108
g-index

186
all docs

186
docs citations

186
times ranked

13542
citing authors

#	ARTICLE	IF	CITATIONS
1	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 60-67.	6.3	5
2	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	6.3	2
3	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	3
4	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , 2021, 26, 302-309.	3.7	9
5	Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, ACITG, BGDO, and FFCD. <i>Journal of Clinical Oncology</i> , 2021, 39, 17-29.	1.6	58
6	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	3.2	3
7	Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma. <i>JAMA Oncology</i> , 2021, 7, 255.	7.1	17
8	Reply to P. Potemski and K. Bujko. <i>Journal of Clinical Oncology</i> , 2021, 39, 1306-1308.	1.6	2
9	Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. <i>Clinical Colorectal Cancer</i> , 2021, 20, 130-136.	2.3	5
10	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1693-1704.	6.3	25
11	422P Age and pathological complete response after neoadjuvant chemoradiation (CRT) with or without oxaliplatin in locally advanced rectal cancer (LARC): Individual patient data (IPD) meta-analysis of three randomised trials (RTs). <i>Annals of Oncology</i> , 2020, 31, S420-S421.	1.2	0
12	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3314-3324.	1.6	139
13	Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer. <i>JAMA Network Open</i> , 2020, 3, e2020425.	5.9	11
14	Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1127-1136.	6.3	24
15	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	2.8	15
16	The future of colorectal cancer research: an interview with Hans Schmoll. <i>Future Oncology</i> , 2020, 16, 2269-2271.	2.4	2
17	Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model. <i>Molecules</i> , 2019, 24, 2865.	3.8	18
18	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	5.9	6

#	ARTICLE	IF	CITATIONS
19	Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.. Journal of Clinical Oncology, 2019, 37, 3502-3502.	1.6	5
20	MODULÂ€”a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1197-1204.	2.5	30
21	What Is the Ongoing Recommendation in the Management of Rectal Cancer?. , 2018, , 59-67.		0
22	Are Capecitabine and 5FU Equivalent When Combined with Radiotherapy?. , 2018, , 259-262.		0
23	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. Journal of the National Cancer Institute, 2018, 110, 638-648.	6.3	90
24	FOCUS4: a new trial design for evaluation of targeted drugs in colorectal cancer?. The Lancet Gastroenterology and Hepatology, 2018, 3, 143-145.	8.1	11
25	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 2018, 100, 35-45.	2.8	29
26	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6.. Journal of Clinical Oncology, 2018, 36, 3500-3500.	1.6	25
27	Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database.. Journal of Clinical Oncology, 2018, 36, 612-612.	1.6	2
28	Change in CEA as an early predictor of progression to first-line systemic therapy in metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 3525-3525.	1.6	3
29	A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group. Annals of Oncology, 2017, 28, 922-930.	1.2	14
30	What is the role of lymph node metastases in the progression of colorectal cancer?. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 633-634.	17.8	16
31	Selective internal radiotherapy in advanced colorectal cancer: only for right-sided tumours?. Lancet Oncology, The, 2017, 18, 1138-1139.	10.7	0
32	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. European Journal of Cancer, 2017, 82, 16-24.	2.8	40
33	Dalotuzumab in chemorefractory <i>KRAS</i> exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. International Journal of Cancer, 2017, 140, 431-439.	5.1	4
34	Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. PLoS ONE, 2017, 12, e0178930.	2.5	18
35	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en CancĂ©rologie Digestive Database. Journal of Clinical Oncology, 2017, 35, 1929-1937.	1.6	37
36	â€œCHARTAâ€ FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancerâ€”Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO.. Journal of Clinical Oncology, 2017, 35, 3533-3533.	1.6	14

#	ARTICLE	IF	CITATIONS
37	Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database.. Journal of Clinical Oncology, 2017, 35, 3535-3535.	1.6	6
38	Impact of FOLFOXIRI and bevacizumab (bev) compared to FOLFOX and bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRC): Analysis of the CHARTA-AIO 0209 trial.. Journal of Clinical Oncology, 2017, 35, 3544-3544.	1.6	2
39	CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)â€”Final results of the randomized phase II trial of the AIO (KRK 0209).. Journal of Clinical Oncology, 2017, 35, 658-658.	1.6	5
40	Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest. PLoS ONE, 2017, 12, e0169921.	2.5	11
41	Phase II-study of sequential high-dose-chemotherapy with paclitaxel, ifosfamide, carboplatin, etoposide(P-ICE) in patients with relapsed or refractory germ cell tumors (GCT).. Journal of Clinical Oncology, 2017, 35, 4552-4552.	1.6	0
42	Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a Î²1â€”integrinâ€”dependent mechanism. International Journal of Cancer, 2016, 138, 964-975.	5.1	20
43	Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC Cancer, 2016, 16, 699.	2.6	54
44	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	4.5	82
45	<sc>MRI</sc> rectal cancer in Australia and New Zealand: An audit from the <sc>PETACC</sc>â€” trial. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 607-615.	1.8	6
46	Targeting HER2: precision oncology for colorectal cancer. Lancet Oncology, The, 2016, 17, 685-686.	10.7	5
47	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. Journal of Geriatric Oncology, 2016, 7, 422-429.	1.0	9
48	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. European Journal of Cancer, 2016, 63, 11-24.	2.8	73
49	Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. Journal of Clinical Oncology, 2016, 34, 843-853.	1.6	128
50	Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Targeted Oncology, 2016, 11, 383-400.	3.6	40
51	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. Journal of Clinical Oncology, 2016, 34, 144-150.	1.6	116
52	Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. Blood, 2016, 128, 511-511.	1.4	13
53	Pazopanib vs pazopanib + gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO.. Journal of Clinical Oncology, 2016, 34, 11004-11004.	1.6	3
54	Influence of KRAS exon 2 mutation variants as well as NRAS- and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab.. Journal of Clinical Oncology, 2016, 34, 3551-3551.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Validity of Adjuvant! Online in elderly patients with stage III colon cancer based on 2,794 patients from the ACCENT database.. Journal of Clinical Oncology, 2016, 34, 3620-3620.	1.6	0
56	Trans-sectoral care in patients with colorectal cancer: Protocol of the randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN). BMC Cancer, 2015, 15, 997.	2.6	6
57	MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside. Critical Reviews in Oncology/Hematology, 2015, 94, 31-44.	4.4	66
58	Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety. Oncologist, 2015, 20, 450-458.	3.7	103
59	Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis. Oncology, 2015, 89, 137-142.	1.9	16
60	Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO Q207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 1355-1369.	10.7	228
61	Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. Journal of Clinical Oncology, 2015, 33, 3733-3740.	1.6	217
62	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, 2015, 33, 22-28.	1.6	87
63	A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 1-10.	2.3	391
64	Time-dependent patterns of recurrence and death in resected colon cancer (CC): Pooled analysis of 12,223 patients from modern trials in the ACCENT database containing oxaliplatin.. Journal of Clinical Oncology, 2015, 33, 3593-3593.	1.6	1
65	Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: A subgroup with improved overall survival.. Journal of Clinical Oncology, 2015, 33, 680-680.	1.6	5
66	Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.. Journal of Clinical Oncology, 2015, 33, 666-666.	1.6	1
67	Determinants of early mortality in 37,568 colon cancer patients participating in 25 clinical trials of the ACCENT database.. Journal of Clinical Oncology, 2015, 33, 6580-6580.	1.6	0
68	A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703.. Journal of Clinical Oncology, 2015, 33, 3049-3049.	1.6	2
69	Abstract B61: Exploratory analyses of the randomized phase 2 IMPACT study: Patients with response to prior induction chemotherapy have improved outcome when treated with the TLR-9 agonist MGN1703. , 2015, , .		0
70	Pulmonary embolism in oncologic patients: frequency and embolus burden of symptomatic and unsuspected events. Acta Radiologica, 2014, 55, 45-53.	1.1	43
71	Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: Results of a multicenter phase I/II study. Acta Oncologica, 2014, 53, 392-398.	1.8	15
72	Benefits and Risks of Colorectal Cancer Screening. Oncology Research and Treatment, 2014, 37, 11-20.	1.2	5

#	ARTICLE	IF	CITATIONS
73	Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, 1481-1492.	10.7	139
74	Crizotinib in refractory <scp>ALK</scp>-positive diffuse large <scp>B</scp>-cell lymphoma: a case report with a short-term response. <i>European Journal of Haematology</i> , 2014, 92, 268-270.	2.2	34
75	Towards improved drugs, combinations and patient selection. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 79-80.	27.6	49
76	Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1615-1624.	2.5	84
77	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3501-3501.	1.6	51
78	Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3503-3503.	1.6	17
79	Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3538-3538.	1.6	2
80	Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3601-3601.	1.6	1
81	Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3537-3537.	1.6	0
82	IMPACT trial: Predictive factors for maintenance therapy with MGN1703 in patients with metastatic colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3615-3615.	1.6	0
83	Optimum Duration of Metastatic Colorectal Cancer Treatment. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 223-229.	0.5	0
84	Right flank pain and high fever in a neutropenic patient with acute lymphoblastic leukaemia. <i>Mycoses</i> , 2013, 56, 90-92.	4.0	2
85	German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. <i>Langenbeck's Archives of Surgery</i> , 2013, 398, 347-375.	1.9	226
86	Improving outcomes in colorectal cancer: Where do we go from here?. <i>European Journal of Cancer</i> , 2013, 49, 2476-2485.	2.8	43
87	Systemic treatment of liver metastases from colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 193-203.	3.2	9
88	Cyclosporine area under the curve after allogeneic hematopoietic stem cell transplantation is an indicator of Epstein-Barr virus DNAemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 133-137.	1.3	7
89	Preoperative Chemoradiotherapy and Postoperative Chemotherapy with Capecitabine and Oxaliplatin vs. Capecitabine Alone in Locally Advanced Rectal Cancer: Response to the Local Treatment After Chemoradiation and Surgery as Secondary Endpoint. <i>Annals of Oncology</i> , 2013, 24, iv120.	1.2	4
90	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3531-3531.	1.6	39

#	ARTICLE	IF	CITATIONS
91	Administration of Chemotherapy by an Arteriovenous Fistula in a Patient with Metastatic Rectal Cancer after Life-Threatening, Port Thrombosis-Associated Cava Superior Syndrome. <i>Onkologie</i> , 2012, 35, 440-442.	0.8	0
92	What Is the Ongoing Recommendation in the Management of Rectal Cancer?. , 2012, , 9-18.		0
93	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 1225-1233.	10.7	484
94	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. <i>Annals of Oncology</i> , 2012, 23, 2479-2516.	1.2	1,233
95	Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. <i>BMC Cancer</i> , 2012, 12, 356.	2.6	23
96	Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). <i>Journal of Clinical Oncology</i> , 2012, 30, 3588-3595.	1.6	194
97	Has the new TNM classification for colorectal cancer improved care?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 119-123.	27.6	163
98	Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).. <i>Journal of Clinical Oncology</i> , 2012, 30, 388-388.	1.6	9
99	IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 633-633.	1.6	2
100	Long-term use of sustained-release cytarabine for symptomatic management and treatment of meningeosis neoplastica.. <i>Journal of Clinical Oncology</i> , 2012, 30, e19579-e19579.	1.6	0
101	A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcinoma: The IMPACT study.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14152-e14152.	1.6	0
102	Crizotinib in ALK-Positive Diffuse Large B-Cell Lymphoma: A Case Report. <i>Blood</i> , 2012, 120, 4862-4862.	1.4	1
103	Adjuvant Therapy for Early Colon Cancer. <i>Drugs</i> , 2011, 71, 2257-2275.	10.9	21
104	Metastases to the Breast from Non-mammary Malignancies. <i>Academic Radiology</i> , 2011, 18, 565-574.	2.5	67
105	Advanced Seminoma and Nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. <i>Urology</i> , 2011, 78, S456-S468.	1.0	6
106	Do we need oncology trials tailored for the elderly or frail?. <i>Lancet</i> , The, 2011, 377, 1725-1727.	18.7	1
107	Sequelae of Treatment in Long-term Survivors of Testis Cancer. <i>European Urology</i> , 2011, 60, 516-526.	1.9	70
108	Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: Report of five cases. <i>Arthritis and Rheumatism</i> , 2011, 63, 2540-2542.	6.7	79

#	ARTICLE	IF	CITATIONS
109	Inflammatory Lesions of the Peritoneum Mimic Carcinomatosis After Treatment With Intravenous Chemotherapy and Intraperitoneal Catumaxomab. <i>Journal of Clinical Oncology</i> , 2011, 29, e644-e646.	1.6	11
110	Perspectives for Onkologie. <i>Onkologie</i> , 2011, 34, 659-659.	0.8	0
111	Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1465-1471.	1.6	669
112	Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity. <i>Histochemistry and Cell Biology</i> , 2010, 134, 197-204.	1.7	30
113	Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. <i>Supportive Care in Cancer</i> , 2010, 18, 423-431.	2.2	215
114	Growth inhibition of colorectal carcinoma by lentiviral <i>TRAIL</i> -transgenic human mesenchymal stem cells requires their substantial intratumoral presence. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2292-2304.	3.6	65
115	Reply to O. Gires et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e241-e242.	1.6	2
116	Safety and efficacy of weekly 5-fluorouracil/ folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 161-174.	3.2	14
117	S-1 for advanced colorectal cancer: do we need another oral fluorouracil prodrug?. <i>Lancet Oncology</i> , The, 2010, 11, 808-809.	10.7	1
118	The role of promoter CpG methylation in the epigenetic control of stem cell related genes during differentiation. <i>Cell Cycle</i> , 2009, 8, 916-924.	2.6	54
119	When Wishful Thinking Leads to a Misty-Eyed Appraisal: The Story of the Adjuvant Colon Cancer Trials With Edrecolomab. <i>Journal of Clinical Oncology</i> , 2009, 27, 1926-1929.	1.6	30
120	Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial. <i>Supportive Care in Cancer</i> , 2009, 17, 1543-1552.	2.2	29
121	Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. <i>European Journal of Cancer</i> , 2009, 45, 1184-1187.	2.8	45
122	Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III. <i>Clinical Colorectal Cancer</i> , 2009, 8, 59-60.	2.3	40
123	Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). <i>Radiotherapy and Oncology</i> , 2009, 92, 148-163.	0.6	275
124	Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1446-1453.	2.5	14
125	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. <i>European Urology</i> , 2008, 53, 478-496.	1.9	488
126	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. <i>European Urology</i> , 2008, 53, 497-513.	1.9	243

#	ARTICLE	IF	CITATIONS
127	Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 60-64.	2.3	28
128	2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II): A Novel Platinum Compound that Overcomes Cisplatin Resistance and Induces Apoptosis by Mechanisms Different from that of Cisplatin. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5413-5422.	6.4	25
129	Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines. <i>Journal of Clinical Oncology</i> , 2008, 26, 2118-2123.	1.6	226
130	To the Editor. <i>Journal of Clinical Oncology</i> , 2008, 26, 2226-2227.	1.6	4
131	Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 5910-5917.	1.6	149
132	Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations. <i>Oncologist</i> , 2007, 12, 1143-1150.	3.7	162
133	Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients. <i>Journal of Clinical Oncology</i> , 2007, 26, 102-109.	1.6	243
134	Bortezomib Inhibits Cell-Cell Adhesion and Cell Migration and Enhances Epidermal Growth Factor Receptor Inhibitor-Induced Cell Death in Squamous Cell Cancer. <i>Cancer Research</i> , 2007, 67, 727-734.	0.9	64
135	Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 4217-4223.	1.6	258
136	Human Chorionic Gonadotropin-Induced Hyperthyroidism in Germ Cell Cancer – a Case Presentation and Review of the Literature. <i>Oncology Research and Treatment</i> , 2007, 30, 330-334.	1.2	7
137	Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?. <i>Lancet, The</i> , 2007, 370, 105-107.	13.7	33
138	CAIRO and FOCUS – Authors' reply. <i>Lancet, The</i> , 2007, 370, 1905.	13.7	2
139	Update on Capecitabine in Colorectal Cancer. <i>Oncologist</i> , 2006, 11, 1003-1009.	3.7	34
140	Presence of Mesenchymal Stem Cells in Human Bone Marrow After Exposure to Chemotherapy: Evidence of Resistance to Apoptosis Induction. <i>Stem Cells</i> , 2006, 24, 2753-2765.	3.2	88
141	Loss of Oct-3/4 Expression in Embryonal Carcinoma Cells Is Associated with Induction of Cisplatin Resistance. <i>Tumor Biology</i> , 2006, 27, 71-83.	1.8	55
142	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Present and Future Role in Gastrointestinal Cancer Treatment: A Review. <i>Oncologist</i> , 2006, 11, 602-611.	3.7	29
143	Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. <i>European Journal of Haematology</i> , 2005, 74, 263-266.	2.2	56
144	Introduction. <i>Oncology</i> , 2005, 69, 1-3.	1.9	31

#	ARTICLE	IF	CITATIONS
145	Chemotherapy in rectal cancer. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 389-400.	2.2	2
146	Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. <i>European Journal of Cancer</i> , 2005, 41, 199-205.	2.8	115
147	Phase I/II Dose-Escalation Study of Pemetrexed plus Irinotecan in Patients with Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 5, 257-262.	2.3	11
148	Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment. <i>Oncology</i> , 2005, 68, 3-11.	1.9	156
149	The Future Development of Bevacizumab in Colorectal Cancer. <i>Oncology</i> , 2005, 69, 34-45.	1.9	10
150	Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment. <i>Journal of Clinical Oncology</i> , 2004, 22, 1209-1214.	1.6	1,007
151	Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 388-94.	2.5	44
152	Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers. <i>Clinical Colorectal Cancer</i> , 2004, 4, 46-50.	2.3	27
153	Cholic acid-carboplatin compounds (CarboChApt) as models for specific drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds. <i>Journal of Inorganic Biochemistry</i> , 2003, 94, 335-342.	3.5	47
154	Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 3098-3104.	1.6	277
155	Biomolecules Linked to Transition Metal Complexes - New Chances for Chemotherapy. <i>Current Medicinal Chemistry</i> , 2003, 10, 2033-2044.	2.4	27
156	Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. <i>Cancer Research</i> , 2003, 63, 513-21.	0.9	95
157	Detection of an Occult B-cell Lymphoma in the Donor's Bone Marrow Prior to HLA-Matched Sibling Transplantation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 169-170.	1.8	0
158	Interdisciplinary Consensus on Diagnosis and Treatment of Testicular Germ Cell Tumors: Result of an Update Conference on Evidence-Based Medicine (EBM). <i>European Urology</i> , 2001, 40, 372-391.	1.9	56
159	Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapy—Results From an International Study Group. <i>Journal of Clinical Oncology</i> , 2001, 19, 2647-2657.	1.6	264
160	New chemotherapy approaches in colorectal cancer. <i>Current Opinion in Oncology</i> , 2001, 13, 275-286.	2.4	57
161	A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001, 127, 96-100.	2.5	12
162	Cyclooxygenase-2: a novel target for cancer chemotherapy?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001, 127, 411-417.	2.5	381

#	ARTICLE	IF	CITATIONS
163	Protective effect of oral phosphatidylcholine on radiation-induced release of intestinal peptidases in rats. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001, 127, 444-448.	2.5	3
164	Integrating Oxaliplatin into the Management of Colorectal Cancer. <i>Oncologist</i> , 2001, 6, 24-28.	3.7	165
165	The Evolution of Fluoropyrimidine Therapy: From Intravenous to Oral. <i>Oncologist</i> , 2001, 6, 3-11.	3.7	40
166	Cisplatin resistance and oncogenes - a review. <i>Anti-Cancer Drugs</i> , 2000, 11, 225-236.	1.4	102
167	Manic episode in an ifosfamide-treated patient. <i>General Hospital Psychiatry</i> , 2000, 22, 52-53.	2.4	10
168	Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin. <i>Anti-Cancer Drugs</i> , 1999, 10, 545-550.	1.4	3
169	Production and pre-clinical significance of haematopoietic peptide growth factors (HPGF) in human non-seminomatous germ cell tumour cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 1998, 124, 435-443.	2.5	5